225 results on '"Arhin, Francis"'
Search Results
2. Supply chain collaboration of Ghana's gold mining industry
3. Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019
4. In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019
5. In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020
6. In vitro Activity of Aztreonam-Avibactam and Comparators Against Metallo-β-Lactamase-Producing Enterobacterales from ATLAS Global Surveillance Program, 2016–2020
7. 2119. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2021
8. 2149. In vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenem-Resistant Enterobacterales With and Without Carbapenemases, ATLAS Global Surveillance Program, 2017–2021
9. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020
10. Analyzing the impact of environmental collaboration among supply chain stakeholders on a firm’s sustainable performance
11. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci
12. Critical Factors of Digital Supply Chains for Organizational Performance Improvement
13. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015
14. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus
15. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus
16. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011–2014
17. 1720. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Urinary Tract Infections Collected During the ATLAS Global Surveillance Program, 2017-2020
18. 1717. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2020
19. 13: IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND AZTREONAM-AVIBACTAM AGAINST CARBAPENEM-NONSUSCEPTIBLE ENTEROBACTERALES ISOLATES COLLECTED IN ASIA/PACIFIC FROM 2017–2020 AS PART OF THE ATLAS GLOBAL SURVEILLANCE PROGRAm
20. 11: IN VITRO ACTIVITY OF AZTREONAM-AVIBACTAM AGAINST ENTEROBACTERALES ISOLATES THAT CARRY METALLO-β-LACTAMASES COLLECTED IN THE ASIA/PACIFIC REGIONAS A PART OF THE ATLAS GLOBAL SURVEILLANCE PROGRAM FROM 2015–2020
21. Antimicrobial Activity of Ceftazidime–Avibactam and Comparators Against Fluoroquinolone-Resistant Klebsiella pneumoniae Collected Globally from Antimicrobial Testing Leadership and Surveillance: 2018–2019
22. Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci
23. Critical Factors of Digital Supply Chains for Organizational Performance Improvement
24. 1225. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales Collected from Geriatric Patients in ICU and non-ICU wards, ATLAS Surveillance Program 2016-2019
25. 1252. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Bloodstream Infections collected during the ATLAS Global Surveillance Program, 2015-2019
26. 1231. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Lower Respiratory Tract Infections Collected During the ATLAS Global Surveillance Program, 2017-2019
27. 1265. In Vitro Activity of Aztreonam-Avibactam against Klebsiella pneumoniae Isolates Analyzed by Epidemic Lineage and Hypervirulence Factors Collected in China as Part of the ATLAS Global Surveillance Study in 2019
28. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019
29. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017
30. Time–kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes
31. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital
32. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis
33. Inhibition of transcription in Staphylococcus aureus by a primary sigma factor-binding polypeptide from phage G1
34. 1567. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Multidrug-Resistant Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2016-2018
35. A new class of small molecule RNA polymerase inhibitors with activity against Rifampicin-resistant Staphylococcus aureus
36. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin
37. Time–kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium
38. Outer Membrane Proteins and Serosubtyping with Outer Membrane Vesicles from Clinical Isolates of Neisseria meningitidis
39. Competition of bacteriophage polypeptides with native replicase proteins for binding to the DNA sliding clamp reveals a novel mechanism for DNA replication arrest in Staphylococcus aureus
40. Effects of disruption of xylanase-encoding genes on the xylanolytic system of Streptomyces lividans
41. Cloning, nucleotide sequence and expression in Streptomyces lividans and Escherichia coli of pabB from Lactococcus lactis subsp. lactis NCDO 496
42. Supplier sustainability performance evaluation and selection: A framework and methodology
43. Sequencing of porA from clinical isolates of Neisseria meningitidis defines a subtyping scheme and its genetic regulation
44. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model
45. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection
46. Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci
47. Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections
48. Comparativein vitroactivity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci
49. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene
50. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.